HIGH confidence
Researched 2026-07-22 22:45 · profile: researcher
Programme Thesis
The NIH STTR (R41/R42) program funds cooperative research and development between a small business and a research institution, with the goal of commercializing innovative technologies that address unmet biomedical needs. It exists to bridge the gap between basic research and marketable products, specifically requiring the small business to perform at least 40% of the work and the research institution at least 30%.
Selection Criteria
• Overall Impact (1-5): Potential to advance scientific knowledge and lead to a commercial product.
• Significance (1-5): Does the project address an important problem? How will it improve health or technology?
• Innovation (1-5): Novelty of the approach (e.g., CCT model, TDA platforms).
• Approach (1-5): Feasibility of research plan, experimental design, and milestones.
• Investigators (1-5): Qualifications of PI (small business) and PD/PI (research institution); Eniola's endorsements from Berridge, Gershman, Daw are strong.
• Environment (1-5): Adequacy of facilities, resources, and collaborative arrangements.
• Commercialization Plan (required): Clear path to market, IP strategy, competitive advantage.
• Eligibility: Small business (≤500 employees, US-based) must be the applicant; research institution (e.g., US university) must be a subcontractor. Eniola must partner with a US small business and a US research institution.
Past Winners / Cohort Profiles
Typical STTR winners are early-stage US biotech startups (e.g., 5-20 employees) paired with academic labs. Examples include companies developing drug screening platforms, neurostimulation devices, or AI-driven diagnostics. Named examples from NIH STTR: 'NeuroLex Laboratories' (neuroscience tools), 'Cognito Therapeutics' (neuromodulation). Eniola's profile aligns with computational tool developers.
Ideal Candidate Fingerprint
A US-based small business CEO with a strong scientific background (often PhD/MD) who has identified a clear unmet need and partnered with a US academic lab. The PI has a track record of grant management and commercialization (e.g., prior SBIR/STTR, patents). The research team includes a leading academic scientist who provides credibility and access to facilities.
Recommended Framing
Eniola should position himself as the scientific lead (not PI, due to US residency requirement) by partnering with a US small business (e.g., a neurotech startup) and a US research institution (e.g., University of Michigan, leveraging Berridge or Daw). Frame the CCT model and IMPRINT platform as a novel drug discovery tool for addiction therapeutics, with a strong commercialization plan (provisional patent, licensing to pharma). Highlight his endorsements from top neuroscientists and his computational platforms as de-risking assets.
Watch Out
Eniola is not a US resident or citizen, and the STTR requires the small business applicant to be US-based. He cannot be the PI of the grant. He must find a US small business partner willing to list him as a key personnel or consultant. His lack of a PhD or MSc may be a disadvantage for the 'Investigators' criterion, but his endorsements and publications mitigate this. The deadline (April 2027) is far off, but he needs to establish a US partnership well in advance.